In the quest for orthopedic innovation, many startups chase the illusion of the quick win—building a product.
Few grasp the eternal game: building a company.
A PRODUCT is a fleeting bet: Craft the finest device, launch it swiftly, seize the market before the sands of capital run dry. It's a sprint against time, fragility baked in.
A COMPANY, however, plays the infinite game. It delivers that first offering, yes—but with equal devotion to forging an antifragile organism. One that pivots with wisdom, iterates with patience, and diversifies like roots spreading deep.
Endurance isn't an accident; it's architecture.
Success or failure alike can shatter a product. A breakthrough knee device soars, then crashes against regulatory winds, supply chain storms, or the shifting tides of demand. In ortho, we've witnessed this cycle endlessly: Startups pour their essence into a single spinal innovation, only to wither under FDA scrutiny, reimbursement wars, or the shadowed dominance of incumbents.But a company compounds. It cultivates talent as leverage, amasses intellectual property as moats, weaves partnerships as networks.
These are the quiet forces that turn survival into sovereignty, birt...
